Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses
Louis de Mestier, Thomas Walter, Hédia Brixi, et al.
Neuroendocrinology (2019) Vol. 108, Iss. 4, pp. 343-353
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
Louis de Mestier, Côme Lepage, Éric Baudin, et al.
Digestive and Liver Disease (2020) Vol. 52, Iss. 5, pp. 473-492
Closed Access | Times Cited: 115
Unlocking the therapeutic potential of drug combinations through synergy prediction using graph transformer networks
Waleed Alam, Hilal Tayara, Kil To Chong
Computers in Biology and Medicine (2024) Vol. 170, pp. 108007-108007
Closed Access | Times Cited: 10
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
Katharine Thomas, Brianne A. Voros, Meghan M. Taylor, et al.
Cancers (2020) Vol. 12, Iss. 1, pp. 206-206
Open Access | Times Cited: 47
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A “Real-World” Data Analysis
Alberto Bongiovanni, Chiara Liverani, Flavia Foca, et al.
Neuroendocrinology (2020) Vol. 111, Iss. 9, pp. 895-906
Closed Access | Times Cited: 31
Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors
Ashley L. Titan, Jeffrey A. Norton, Andrea T. Fisher, et al.
JAMA Network Open (2020) Vol. 3, Iss. 11, pp. e2024318-e2024318
Open Access | Times Cited: 29
Chemotherapy in Neuroendocrine Tumors
Satya Das, Taymeyah Al‐Toubah, Jonathan Strosberg
Cancers (2021) Vol. 13, Iss. 19, pp. 4872-4872
Open Access | Times Cited: 24
Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
Giulia Arrivi, Monica Verrico, Michela Roberto, et al.
Cancer Management and Research (2022) Vol. Volume 14, pp. 3507-3523
Open Access | Times Cited: 17
Gastrointestinal neuroendocrine tumor syndromes (GI-NETS)
Tetsuhide Ito, Robert T. Jensen
Elsevier eBooks (2025)
Closed Access
Surgical Management of Neuroendocrine Tumor Liver Metastases
Catherine G. Tran, Scott K. Sherman, Chandrikha Chandrasekharan, et al.
Surgical Oncology Clinics of North America (2020) Vol. 30, Iss. 1, pp. 39-55
Open Access | Times Cited: 26
Small Bowel Neuroendocrine Tumors
Catherine G. Tran, Scott K. Sherman, James R. Howe
Current Problems in Surgery (2020) Vol. 57, Iss. 12, pp. 100823-100823
Open Access | Times Cited: 22
Carcinoid Heart Disease: How to Diagnose and Treat in 2020?
Barbara Bober, Marek Saracyn, Maciej Kołodziej, et al.
Clinical Medicine Insights Cardiology (2020) Vol. 14, pp. 117954682096810-117954682096810
Open Access | Times Cited: 21
The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States
Xiaobai Liu, B. Chen, J. Chen, et al.
Journal of Endocrinological Investigation (2022) Vol. 46, Iss. 7, pp. 1373-1384
Closed Access | Times Cited: 13
Critical appraisal of MGMT in digestive NET treated with alkylating agents
Louis de Mestier, Anne Couvelard, Anela Blažević, et al.
Endocrine Related Cancer (2020) Vol. 27, Iss. 10, pp. R391-R405
Open Access | Times Cited: 20
Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
Vera G. Megdanova-Chipeva, Ángela Lamarca, Alison Backen, et al.
Cancers (2020) Vol. 12, Iss. 7, pp. 1988-1988
Open Access | Times Cited: 18
Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors
Ugo Marchèse, Martin Gaillard, Anna Pellat, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 433-433
Open Access | Times Cited: 11
Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies
Lingaku Lee, Irene Ramos-Álvarez, Robert T. Jensen
Cancers (2022) Vol. 14, Iss. 5, pp. 1250-1250
Open Access | Times Cited: 11
Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis
Francesca Spada, Patrick Maisonneuve, Caterina Fumagalli, et al.
Endocrine (2020) Vol. 72, Iss. 1, pp. 268-278
Closed Access | Times Cited: 16
The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)
Wenming Wu, J Chen, Christopher Bai, et al.
(2021) Vol. 59, Iss. 6, pp. 401-421
Closed Access | Times Cited: 14
Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms
Lola‐Jade Palmieri, Solène Dermine, Amélie Barré, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 6, pp. 1860-1860
Open Access | Times Cited: 14
FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
Caroline Lacombe, Marine Perrier, Olivia Hentic, et al.
Journal of Neuroendocrinology (2022) Vol. 35, Iss. 1
Open Access | Times Cited: 8
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)
Giuseppe Lamberti, Natalie Prinzi, Alberto Bongiovanni, et al.
Diagnostics (2023) Vol. 13, Iss. 9, pp. 1595-1595
Open Access | Times Cited: 4
The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors
Mauro Cives, Eleonora Pellè, Davide Quaresmini, et al.
Current Treatment Options in Oncology (2019) Vol. 20, Iss. 9
Closed Access | Times Cited: 12
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O 6 -Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)
Thomas Walter, Thierry Lecomte, Julien Hadoux, et al.
Journal of Clinical Oncology (2024) Vol. 43, Iss. 8, pp. 960-971
Closed Access | Times Cited: 1
The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)
Wenming Wu, Jie Chen, Chunmei Bai, et al.
Journal of Pancreatology (2021) Vol. 4, Iss. 1, pp. 1-17
Open Access | Times Cited: 9
Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma
Thomas Couronne, Paul Girot, Julien Hadoux, et al.
Endocrine Connections (2020) Vol. 9, Iss. 6, pp. 498-505
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top